Outcome Of Prostate Cancer Patients With Initial PSA≥20ng/ml Undergoing Radical Prostatectomy
Main Category: Prostate / Prostate CancerAlso Included In: Urology / Nephrology; Men's health
Article Date: 11 Jan 2008 - 0:00 PDT
| Patient / Public: | ![]() |
5 (1 votes) |
| Healthcare Prof: | ![]() |
UroToday.com- Patients presenting with a PSA >20ng/ml and a diagnosis of prostate cancer (CaP) are often not offered radical prostatectomy (RP) due to the concern over metastasis and likelihood of failure. In the October issue of European Urology, Dr. Zwergel and colleagues from Germany report on a retrospective series of 275 patients with a PSA >20ng/ml who underwent RP. Overall survival (OS) and disease specific survival (DSS) at 15 years was 58% and 71%, suggesting that this is an option for this group of patients.
The 275 patient cohort underwent surgery between 1986 and 2005. Prior to 2000, men received adjuvant androgen deprivation therapy (ADT) for pT3-4 or N+ disease but after the year 2000 men were treated for disease progression only. All men had a negative metastatic evaluation preoperatively.
Median patient age was 64 years and the majority were Gleason score 7 or above. Adjuvant ADT was given to 129 patients. Of the 146 men who underwent surveillance, 36 received delayed ADT. Four patients died in the peri-operative period. At the time of this report, 235 men are still alive with 92(33.5%) having had a biochemical recurrence. Of the 40 patients who died, death was attributed to CaP in 22. Median follow-up was 42 months. OS and DSS at 5, 10, and 15 years were 87% (93%), 70% (83%), and 58% (71%). PSA progression free survival in patient with deferred ADT was 53% at 5 years, compared to 76% for those on immediate ADT. A potential benefit not reported in this study is decreased morbidity secondary to local control of surgery.
Zwergel U, Suttmann H, Schroeder T, Siemer S, Wullich B, Kamradt J, Lehmann J, Stoeckle M
Eur Urol. 52(4): 1058- 1066, October 2007
doi:10.1016/j.eururo.2007.03.056
Reported by UroToday.com Contributing Editor Christopher P. Evans, M.D
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to: www.urotoday.com
----------------------------
Copyright © 2007 - UroToday
Reproduced for Medical News Today with permission of UroToday.
----------------------------
Visit our prostate / prostate cancer section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/93663.php>
APA
http://www.medicalnewstoday.com/releases/93663.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




